

Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following drug types best describes the mechanism of action of mosunetuzumab, a novel agent under investigation for patients with follicular lymphoma (FL)?**
 - Anti-CD20 monoclonal antibody
 - Bispecific antibody**
 - EZH2 inhibitor
 - Dual PI3 kinase inhibitor
- 2. Which of the following PI3 kinase inhibitors is FDA approved for patients with relapsed or refractory FL after at least 2 prior therapies?**
 - Idelalisib only
 - Copanlisib only
 - Duvelisib only
 - Idelalisib and copanlisib only
 - Idelalisib, copanlisib and duvelisib**
- 3. Polatuzumab vedotin is currently approved in combination with which agent or regimen for the treatment of recurrent diffuse large B-cell lymphoma?**
 - Bendamustine/rituximab**
 - Rituximab
 - Obinutuzumab
 - None of the above — polatuzumab vedotin is approved as monotherapy in this setting
- 4. Which of the following drug types best describes pirtobrutinib, a novel agent under investigation for patients with mantle cell lymphoma?**
 - Bcl-2 inhibitor
 - Covalent Bruton tyrosine kinase (BTK) inhibitor
 - Noncovalent BTK inhibitor**
 - Antibody-drug conjugate